OLMA May 15th Options Begin Trading

Olema Pharmaceuticals (OLMA) stock trades at $25.64; a $25 put is bid at $4.00 (net effective purchase price $21.00) with a 65% chance of expiring worthless, implying a 16.00% return (55.64% annualized). A $26 call is bid at $4.60 for a covered-call strategy that would produce a 19.34% total return to be called at the May 15 expiration, with a 37% chance of expiring worthless and a 17.94% YieldBoost (62.39% annualized). Implied volatilities are elevated at 123% (put) and 129% (call) versus a trailing 12-month volatility of 120%, highlighting significant option premium for yield-focused strategies.

Analysis

Market structure: High IV (put 123%, call 129% vs realized 120%) signals that OLMA is trading like a binary biotech event and directly benefits option sellers, market-makers (NDAQ fee flow), and income-seeking buyers who want cheap entry via cash-secured puts. Losses concentrate with call buyers if a large upside occurs and with holders if a negative trial or secondary dilutes the stock; the quoted YieldBoosts (16%–18% for ~3.5 month May 15 expiry, annualized 55%–62%) quantify this skew.

Risk assessment: Tail risks are regulatory/trial failure or an equity secondary — any single-event negative outcome could exceed a 50% drop (historical biotech binaries). Immediate horizon (days) is dominated by IV moves and flow; short-term (~weeks–3.5 months to May 15) centers on option expiries and potential data/filings; long-term (quarters) hinges on cash runway and trial readouts. Hidden risks: assignment creates concentrated long stock exposure and margin; second-order effect is forced selling into low-liquidity windows.

Trade implications: Favor defined-risk option sells rather than naked exposure—credit spreads or covered calls capture elevated premium while capping downside. Relative play: overweight OLMA via cash-secured or credit-spread put (small size) vs short small-cap biotech ETF (XBI) to hedge market beta. Cross-asset: a big adverse biotech shock would push risk-off flows into bonds and the dollar; monitor Treasury moves as a risk barometer.

Contrarian angle: The market’s comfort with selling premium (65% put-expiry odds) may underprice catastrophic downside; implied vs realized parity means selling is not a free lunch. Historical parallels (biotech trial binary failures) show realized drops often exceed IV-calibrated risk in the short window; unintended consequence of these income trades is concentrated assignment and forced dilution during secondary offerings.

Key Decisions for Investors

• Establish a limited cash-secured put credit spread on OLMA: sell May 15 $25 put and buy May 15 $20 put, size ≤1% portfolio notional; only execute if net credit ≥ $2.00 (implies max loss ≤ $5.00 - credit). Close or roll if OLMA < $18.50 or IV > 170%.
• If bullish and willing to own shares, buy 100 OLMA and sell May 15 $26 covered call to pocket ~$4.60; position size 0.5–1% portfolio. If stock rallies >30% (~$33), buy back the call to preserve upside or roll up-and-out.
• Avoid naked short puts >2% portfolio. If selling naked puts as a liquidity play, set a hard buy-to-close at a 10% drop below your post-premium cost basis ($21 → trigger at $18.90) or upon any S-1/secondary filing within 60 days.
• Risk-monitor: scan SEC filings and Option Open Interest daily for OLMA; if a new shelf/ATM appears or unusual block puts >50k contracts print, reduce OLMA option exposure by 50% within 48 hours.